Share-based Payment Arrangement, Expense of BeOne Medicines Ltd. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BeOne Medicines Ltd. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • BeOne Medicines Ltd. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $140,786,000, a 23% increase year-over-year.
  • BeOne Medicines Ltd. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $494,572,000, a 16% increase year-over-year.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2024 was $441,793,000, a 20% increase from 2023.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $367,588,000, a 21% increase from 2022.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $303,162,000, a 26% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BeOne Medicines Ltd. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $494,572,000 $140,786,000 +$26,183,000 +23% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $468,389,000 $150,553,000 +$19,859,000 +15% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $448,530,000 $95,451,000 +$6,737,000 +7.6% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $441,793,000 $107,782,000 +$15,030,000 +16% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $426,763,000 $114,603,000 +$18,484,000 +19% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $408,279,000 $130,694,000 +$27,365,000 +26% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $380,914,000 $88,714,000 +$13,326,000 +18% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $367,588,000 $92,752,000 +$14,626,000 +19% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $352,962,000 $96,119,000 +$17,943,000 +23% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $335,019,000 $103,329,000 +$22,024,000 +27% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $312,995,000 $75,388,000 +$9,833,000 +15% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $303,162,000 $78,126,000 +$15,115,000 +24% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $288,047,000 $78,176,000 +$11,099,000 +17% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $276,948,000 $81,305,000 +$16,514,000 +25% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $260,434,000 $65,555,000 +$19,722,000 +43% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $240,712,000 $63,011,000 +$13,550,000 +27% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $227,162,000 $67,077,000 +$16,780,000 +33% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $210,382,000 $64,791,000 +$19,323,000 +42% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $191,059,000 $45,833,000 +$7,578,000 +20% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $183,481,000 $49,461,000 +$11,119,000 +29% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
Q3 2020 $172,362,000 $50,297,000 +$13,479,000 +37% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $158,883,000 $45,468,000 +$12,866,000 +39% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $146,017,000 $38,255,000 +$11,863,000 +45% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $134,154,000 $38,342,000 +$12,384,000 +48% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $121,770,000 $36,818,000 +$11,686,000 +46% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $110,084,000 $32,602,000 +$13,961,000 +75% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $96,123,000 $26,392,000 +$8,996,000 +52% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $87,127,000 $25,958,000 +$9,496,000 +58% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $77,631,000 $25,132,000 +$11,805,000 +89% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $65,826,000 $18,641,000 +$11,559,000 +163% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $54,267,000 $17,396,000 +$11,404,000 +190% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $42,863,000 $16,462,000 +$12,515,000 +317% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $30,348,000 $13,327,000 +$10,548,000 +380% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $19,800,000 $7,082,000 +$5,797,000 +451% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $14,003,000 $5,992,000 +$3,378,000 +129% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $10,625,000 $3,947,000 +$1,779,000 +82% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $8,846,000 $2,779,000 -$2,040,000 -42% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3
Q2 2016 $10,886,000 $1,285,000 +$375,000 +41% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $10,511,000 $2,614,000 +$300,000 +13% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $10,211,000 $2,168,000 01 Oct 2015 31 Dec 2015 10-K 28 Feb 2018 2017 FY
Q3 2015 $4,819,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $910,000 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016 2016 Q2
Q1 2015 $2,314,000 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1

BeOne Medicines Ltd. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $441,793,000 +$74,205,000 +20% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $367,588,000 +$64,426,000 +21% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $303,162,000 +$62,450,000 +26% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $240,712,000 +$57,231,000 +31% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $183,481,000 +$49,327,000 +37% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 $134,154,000 +$47,027,000 +54% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $87,127,000 +$44,264,000 +103% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $42,863,000 +$32,238,000 +303% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $10,625,000 +$414,000 +4.1% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $10,211,000 +$3,574,000 +54% 01 Jan 2015 31 Dec 2015 10-K 28 Feb 2018 2017 FY
2014 $6,637,000 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.